Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5211614 | 0.93 | TSHR (0.40) | LMNAMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL14609769 | 0.89 | SMN1; SMN2 (0.41) | LMNAMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL5209936 | 0.88 | LMNA (0.50) | LMNAMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL14609867 | 0.88 | SMN1; SMN2 (0.40) | LMNAMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL14609887 | 0.88 | ATM (0.42) | LMNAMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL5209966 | 0.86 | SMN1; SMN2 (0.46) | LMNAMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL5206933 | 0.85 | ENPP2 (0.47) | LMNAMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL5216367 | 0.85 | SMN1; SMN2 (0.42) | LMNAMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL5212575 | 0.85 | ENPP2 (0.49) | LMNAMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL5207866 | 0.85 | GABRA1 (0.35) | KMT2ASMN1; SMN2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183276-B2 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20050090534-A1 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1486490-A1 | AZOLE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090534-A1 | Azole compounds | AHR, NR0B2, NR2C2 | LMNA 4253/4885MEN1 1626/4885KMT2A 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.